170 related articles for article (PubMed ID: 33002130)
1. CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.
Leong S; Inglott S; Papaleonidopoulou F; Orfinada K; Ancliff P; Bartram J; Carpenter B; Fielding AK; Ghorashian S; Grandage V; Gupta R; Hough R; Khwaja A; Pavasovic V; Rao A; Samarasinghe S; Vora A; Mansour MR; O'Connor D
Blood Adv; 2020 Oct; 4(19):4665-4668. PubMed ID: 33002130
[No Abstract] [Full Text] [Related]
2. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
3. Investigational treatment options in phase I and phase II trials for relapsed or refractory acute lymphoblastic leukemia in pediatric patients.
Asare JM; Rabik CA; Muller B; Brown PA; Cooper S
Expert Opin Investig Drugs; 2021 Jun; 30(6):611-620. PubMed ID: 33896328
[No Abstract] [Full Text] [Related]
4. Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers.
Jiménez-Reinoso A; Tirado N; Martinez-Moreno A; Díaz VM; García-Peydró M; Hangiu O; Díez-Alonso L; Albitre Á; Penela P; Toribio ML; Menéndez P; Álvarez-Vallina L; Sánchez Martínez D
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564128
[TBL] [Abstract][Full Text] [Related]
5. Relapsed/Refractory T- Acute Lymphoblastic Leukemia - Current Options and Future Directions.
Jeha S
Indian J Pediatr; 2024 Feb; 91(2):168-175. PubMed ID: 37642889
[TBL] [Abstract][Full Text] [Related]
6. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
DeAngelo DJ
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
[TBL] [Abstract][Full Text] [Related]
7. Analysis of 60 patients with relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma treated with CD7-targeted chimeric antigen receptor-T cell therapy.
Zhang X; Yang J; Li J; Qiu L; Zhang J; Lu Y; Zhao YL; Jin D; Li J; Lu P
Am J Hematol; 2023 Dec; 98(12):1898-1908. PubMed ID: 37740926
[TBL] [Abstract][Full Text] [Related]
8. Dismal outcome of relapsed or primary refractory adult T-cell lymphoblastic lymphoma: A retrospective study from China.
Chen H; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Yang S; Gui L; Sun Y; Shi Y
Asia Pac J Clin Oncol; 2022 Apr; 18(2):e87-e95. PubMed ID: 34161657
[TBL] [Abstract][Full Text] [Related]
9. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.
Sánchez-Martínez D; Baroni ML; Gutierrez-Agüera F; Roca-Ho H; Blanch-Lombarte O; González-García S; Torrebadell M; Junca J; Ramírez-Orellana M; Velasco-Hernández T; Bueno C; Fuster JL; Prado JG; Calvo J; Uzan B; Cools J; Camos M; Pflumio F; Toribio ML; Menéndez P
Blood; 2019 May; 133(21):2291-2304. PubMed ID: 30796021
[TBL] [Abstract][Full Text] [Related]
10. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela M; Corral D; Carrasco P; Fernández L; Valentín J; González B; Escudero A; Balas A; de Paz R; Torres J; Leivas A; Martinez-Lopez J; Pérez-Martínez A
Cancer Lett; 2018 May; 422():107-117. PubMed ID: 29477379
[TBL] [Abstract][Full Text] [Related]
11. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotypic analysis of T-acute lymphoblastic leukemia. A CD5-based ETP-ALL perspective of non-ETP T-ALL.
Chopra A; Bakhshi S; Pramanik SK; Pandey RM; Singh S; Gajendra S; Gogia A; Chandramohan J; Sharma A; Kumar L; Seth R; Rai S; Kumar R
Eur J Haematol; 2014 Mar; 92(3):211-8. PubMed ID: 24329989
[TBL] [Abstract][Full Text] [Related]
13. Clinical utilization of blinatumomab and inotuzumab immunotherapy in children with relapsed or refractory B-acute lymphoblastic leukemia.
Contreras CF; Higham CS; Behnert A; Kim K; Stieglitz E; Tasian SK
Pediatr Blood Cancer; 2021 Jan; 68(1):e28718. PubMed ID: 33098744
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
[TBL] [Abstract][Full Text] [Related]
15. Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
DuVall AS; Wesevich A; Larson RA
Curr Hematol Malig Rep; 2023 Dec; 18(6):217-225. PubMed ID: 37490229
[TBL] [Abstract][Full Text] [Related]
16. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
17. Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
Huang YH; Wan CL; Dai HP; Xue SL
Ann Hematol; 2023 Aug; 102(8):2001-2013. PubMed ID: 37227492
[TBL] [Abstract][Full Text] [Related]
18. Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia.
Rytting M; Triche L; Thomas D; O'Brien S; Kantarjian H
Pediatr Blood Cancer; 2014 Feb; 61(2):369-72. PubMed ID: 24000241
[TBL] [Abstract][Full Text] [Related]
19. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
[TBL] [Abstract][Full Text] [Related]
20. CD38: A target in relapsed/refractory acute lymphoblastic leukemia-Limitations in treatment and diagnostics.
Vakrmanová B; Nováková M; Říha P; Žaliová M; Froňková E; Mejstříková E; Starý J; Hrušák O; Šrámková L
Pediatr Blood Cancer; 2022 Sep; 69(9):e29779. PubMed ID: 35592935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
